OBPM_PANDA2026: Evaluation of the Performance and Safety of the Aktiia Periodic Optical Blood Pressure Monitoring Device

NCT07507903 | Not Yet Recruiting FDA Device

• 1 other identifier: OBPM_PANDA2026
• Study Type: interventional
• Target: 200
• Locations: 1 country
• Sites: 1

Brief Summary

This study, with N = 85 participants minimum over 3 visits spread over 7 days, has been designed to assess the accuracy and precision of the Blood Pressure and pulse rate values as generated by Aktiia.product-G1-US for up to 7 days after initialization in a cohort of subjects representative of the US population.

Conditions

Hypertension

Keywords

blood pressure

Outcome Measures

Primary Outcomes (2)

• Blood pressure mean value of differences

  The mean value of the differences between Aktiia.product-G1-US and double auscultation blood pressure measurements.

  7 days

• Blood pressure standard deviation of differences

  The standard deviation of the differences between Aktiia.product-G1-US and double auscultation blood pressure measurements.

  7 days

Secondary Outcomes (1)

• Heart rate root-mean-square error

  7 days

Study Arms (1)

Aktiia.product-G1-US device under test

OTHER

Blood pressure and pulse rate measurements will be taken at different timepoints with the device under test and references.

Device: Device under test evaluation against references

Interventions

Device under test evaluation against references DEVICE

Blood pressure and pulse rate measurements will be taken at different timepoints with the device under test and references. Main references: Cuff for double auscultation for blood pressure and Electrocardiogram for pulse rate.

Aktiia.product-G1-US device under test

Eligibility Criteria

• Age: 22 Years - 59 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Participants must be able to provide informed consent to participate.
• Participants must be willing and able to comply with all of the study procedures and return for a second visit one week later.
• Participants must be 22 to 59 years of age.
• Participants or witnesses must be able to read or write in English.

You may not qualify if:

• Participants with compromised circulation, injury, or physical malformation of the equipment test sites or other sensor sites which would limit the ability to test sites needed for the study. (Note: Certain malformations may still allow participants to participate if the condition is noted and would not affect the sites utilized.)
• Female participants who are known to be pregnant or who are trying to get pregnant confirmed by a visit 1 and, if applicable, visit 2 positive urine pregnancy test, unless the study participants are known to be not of child-bearing potential .
• Participants with known history of clotting disorders or blood clots, or currently taking a prescription blood thinner.
• Other known health conditions that will prevent safe participation in the study upon disclosure in Health Assessment Short Form or verbally.
• Participants suffering from sporadic or sustained cardiac arrhythmias that can lead to weak or unstable pressure pulses including but not limited to tachycardia (heart rate at rest \> 120bpm) and atrial fibrillation.
• Participants suffering from sporadic or sustained reduction of peripheral perfusion that can lead to weak or unstable pressure pulses including but not limited to: Raynaud's disease, diabetes (Type I and Type II), renal dysfunctions (eGFR \< 60mL / min / 1.73 m2), hyper- / hypothyroidism, pheochromocytoma, arteriovenous fistula, and valvular heart diseases.
• A wrist circumference below 14 cm or above 23 cm.
• An upper-arm circumference \<22 cm or \> 42cm.
• Any subject that, in the opinion of the investigator, does not exhibit any phenotype relevant to the objectives of this study.
• Any condition or circumstance that, in the opinion of the investigator, may preclude study completion, interfere with accurate data collection, or bias the results, by instance a subject presenting a lateral Blood Pressure difference at screening of more than 15 mmHg for the systolic and/or more than 10 mmHg for the diastolic.

Sponsors & Collaborators

• Aktiia SA: lead

Study Sites (1)

Parameters Research Laboratory

Broomfield, Colorado, 80021, United States

Location

MeSH Terms

Conditions

Hypertension

Condition Hierarchy (Ancestors)

Vascular Diseases; Cardiovascular Diseases

Central Study Contacts

Anne Fedor Chief Clinical Research Officer

CONTACT

303-993-5217; anne@parameterslab.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: OTHER
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 27, 2026
• First Posted: April 2, 2026
• Study Start: April 20, 2026
• Primary Completion (Estimated): December 31, 2026
• Study Completion (Estimated): December 31, 2026
• Last Updated: April 17, 2026

Record last verified: 2026-04

Locations

US (1)